Larimar Therapeutics Inc
F:ZA71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Larimar Therapeutics Inc
F:ZA71
|
US |
|
Landec Corp
F:LDE
|
US |
|
C
|
CombinedX AB (publ)
F:K13
|
SE |
|
F
|
Fomento de Construcciones y Contratas SA
XMUN:FCC
|
ES |
|
Kid ASA
F:97Q
|
NO |
|
T
|
Texas Pacific Land Corp
F:9WY
|
US |
|
L
|
Lloyds Banking Group PLC
F:LLD2
|
UK |
|
B
|
Bendigo and Adelaide Bank Ltd
SWB:BDJ
|
AU |
|
E
|
Endesa SA
XMUN:ENA
|
ES |
|
C
|
China Literature Ltd
F:C2X
|
CN |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
IE |
|
W
|
WPP PLC
DUS:0WP
|
UK |
|
A
|
Allgeier SE
XMUN:AEIN
|
DE |
Shareholder Yield
Current shareholder yield for 
ZA71 is
hidden
.
Peers Comparison
Shareholder Yield
Buybacks
Buyback Yield measures how much a company reduces its outstanding shares through repurchases, expressed as a percentage.
This metric directly reflects the company’s efforts to return value to shareholders. By reducing the number of shares, buybacks can increase earnings per share and potentially boost the stock's price.
Peers Comparison
Buybacks
Debt Paydown
Debt Paydown Yield measures the amount of debt a company repays within a specific period, shown as a percentage of its market capitalization.
This metric indicates how the company is using its capital to decrease financial liabilities, which can strengthen its financial health and potentially enhance shareholder value.
Peers Comparison
Debt Paydown
Price Appreciation
ZA71 Price
Larimar Therapeutics Inc
| Average Annual Return | -8.04% |
| Standard Deviation of Annual Returns | 37.63% |
| Max Drawdown | -88% |
| Market Capitalization | 360.5m EUR |
| Shares Outstanding | 63 802 000 |
| Percentage of Shares Shorted |
N/A
|
